Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhengzhou Univ. METTL3 compound 30t
- Development stage
- Unknown
- Lead developer
- Zhengzhou University
01
Overview
Zhengzhou Univ. METTL3 compound 30t: sourced facts only. name: "Compound 30t exhibited excellent inhibitory activity against METTL3 with an IC50 value of 45.31 nM and good antiproliferation ability in ovarian cancer SKOV3 and acute myeloid leukemia MOLM-13 cells with IC50 values of 6.42 μM and 12.34 μM, respectively." [PMID:40961538]; target: "Compound 30t exhibited excellent inhibitory activity against METTL3 with an IC50 value of 45.31 nM and good antiproliferation ability in ovarian cancer SKOV3 and acute myeloid leukemia MOLM-13 cells with IC50 values of 6.42 μM and 12.34 μM, respectively." [PMID:40961538]; developer: "Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China; Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou 450052, China; Henan Sino-US International Joint Laboratory of Clinical Pharmacy, Zhengzhou 450052, China." [PMID:40961538]; stage: "Compound 30t exhibited excellent inhibitory activity against METTL3 with an IC50 value of 45.31 nM and good antiproliferation ability in ovarian cancer SKOV3 and acute myeloid leukemia MOLM-13 cells with IC50 values of 6.42 μM and 12.34 μM, respectively." [PMID:40961538]
02
Targets
METTL3 (Methyltransferase-like protein 3)
Beyond the preview
Go deeper on Zhengzhou Univ. METTL3 compound 30t.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhengzhou Univ. METTL3 compound 30t.